4/A: CareDx Director Michael Goldberg Corrects Stock Option Exercise Price in Amended SEC Filing

Michael Goldberg, a director at CareDx, Inc., filed an amendment to a previous SEC Form 4 to correct the exercise price of a stock option.

Summary

• Michael Goldberg, a director of CareDx, Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of a stock option previously reported on the original Form 4.
• The stock option grants Goldberg the right to buy 16,048 shares of CareDx common stock.
• The corrected exercise price is $14.19.
• The options vest monthly, starting July 14, 2024, and continuing through June 14, 2025.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previously filed form, indicating standard corporate governance practices. There is no indication of positive or negative sentiment, but the correction itself suggests attention to detail.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology and healthcare industries where stock options are frequently used as incentives.

Comparison to Industry Standards

• Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech industry.
• The vesting schedule of 1/12th monthly over a year is a fairly standard vesting arrangement.
• Comparing the exercise price and the number of shares to similar companies would require a broader analysis of executive compensation packages within the peer group.

Stakeholder Impact

• The correction of the stock option exercise price ensures accurate reporting and transparency for shareholders.
• The vesting schedule provides an incentive for the director to remain with the company and contribute to its success.

Key Dates